ES2114654T3 - Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta. - Google Patents

Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta.

Info

Publication number
ES2114654T3
ES2114654T3 ES94201597T ES94201597T ES2114654T3 ES 2114654 T3 ES2114654 T3 ES 2114654T3 ES 94201597 T ES94201597 T ES 94201597T ES 94201597 T ES94201597 T ES 94201597T ES 2114654 T3 ES2114654 T3 ES 2114654T3
Authority
ES
Spain
Prior art keywords
alkyl
aryl
interleukin
chr5
sulphonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94201597T
Other languages
English (en)
Inventor
Roland E Dolle
Denton W Hoyer
Stanley J Schmidt
Tina M Ross
James M Rinker
Mark A Ator
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2114654T3 publication Critical patent/ES2114654T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DE LA FORMULA I Y SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS MISMOS, EN DONDE R ES HALOGENO, OXIGENO UNIDO A UN GRUPO SALIENTE QUE INCLUYE ETER AROMATICO, ESTER AROMATICO, SULFONATO DE ALQUILO, SULFONATO DE ARILO, FOSFONATO DE ALQUILO, FOSFONATO DE ARILO, FOSFATO DE ALQUILO O FOSFATO DE ARILO; R2 ES OR5, NH(CHR5)MCOOR5, NH(CHR5)MCON(R5)R6 NR5R6 O NH(CHR5)NOH; R3 ES H O ALQUILO; R4 ES H, ARIL SUSTITUIDO O INSUSTITUIDO, HETEROARILO O ALQUILO; R5 Y R6 SON INDEPENDIENTEMENTE H, ALQUILO INFERIOR, ARILO, HETEROARILO, ARALQUILO, HETEROARALQUILO O CICLOALQUILO INFERIOR; M = 1-6; Y N = 2-6. TAMBIEN SE PRESENTAN LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN LOS COMPUESTOS; Y UN METODO PARA INHIBIR LA ACTIVIDAD DE LA PROTEASA DE LA INTERLEUQUINA 1-(BETA) EN UN MAMIFERO UTILIZANDO LOS COMPUESTOS Y LAS COMPOSICIONES DE LA INVENCION.
ES94201597T 1993-06-08 1994-06-04 Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta. Expired - Lifetime ES2114654T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7391493A 1993-06-08 1993-06-08

Publications (1)

Publication Number Publication Date
ES2114654T3 true ES2114654T3 (es) 1998-06-01

Family

ID=22116553

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94201597T Expired - Lifetime ES2114654T3 (es) 1993-06-08 1994-06-04 Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta.

Country Status (18)

Country Link
US (3) US6121266A (es)
EP (1) EP0628550B1 (es)
JP (1) JPH0769894A (es)
KR (1) KR950000673A (es)
AT (1) ATE163412T1 (es)
AU (1) AU693786B2 (es)
CA (1) CA2125359A1 (es)
CZ (1) CZ140194A3 (es)
DE (1) DE69408598T2 (es)
DK (1) DK0628550T3 (es)
ES (1) ES2114654T3 (es)
FI (1) FI942693A7 (es)
HU (1) HUT67413A (es)
IL (1) IL109918A0 (es)
NO (1) NO306061B1 (es)
NZ (1) NZ260698A (es)
RU (1) RU94019984A (es)
SK (1) SK69794A3 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
ES2114654T3 (es) 1993-06-08 1998-06-01 Vertex Pharma Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta.
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
CA2215211A1 (en) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
GB9715640D0 (en) * 1997-07-24 1997-10-01 M J Highway Technology Limited Road repair material
US6348468B1 (en) * 1997-11-19 2002-02-19 Kowa Co., Ltd. Pyridazine compounds and compositions containing the same
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) * 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
EP1712239A3 (en) * 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
EP2264014A1 (en) 2001-08-31 2010-12-22 Université Louis Pasteur Substituted pyridazines as anti-inflammatory agents and protein kinase inhibitors
TWI314455B (en) * 2002-12-10 2009-09-11 Nippon Kayaku Kk 3-phenyl-cinnoline derivatives and anti-tumor agent containing the same
RU2005132167A (ru) 2003-03-18 2006-05-10 Кова Ко., Лтд. (Jp) Водорастворимые производные фенилпиридазина и лекарственные средства, содержащие их
AU2004298486A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
EP1720893B1 (en) 2004-02-26 2014-08-13 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
WO2005115362A1 (en) * 2004-05-15 2005-12-08 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CA2589106C (en) 2004-11-02 2015-07-21 Northwestern University Pyridazine compounds, compositions and methods and their use in treating inflammatory diseases
JP2008518955A (ja) 2004-11-02 2008-06-05 ノースウェスタン ユニバーシティ ピリダジン化合物および方法
US8158627B2 (en) 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
AU2007243280A1 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
WO2007127475A2 (en) * 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
WO2012075393A2 (en) * 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
KR102419136B1 (ko) 2017-06-15 2022-07-08 삼성전자주식회사 다채널 특징맵을 이용하는 영상 처리 장치 및 방법
CA3105657A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
AU2019302534B2 (en) 2018-07-09 2024-10-03 Lieber Institute, Inc. Pyridazine compounds for inhibiting NaV1.8
WO2026082873A1 (en) 2024-10-17 2026-04-23 Institut National de la Santé et de la Recherche Médicale Use of caspase-1 inhibitors for treating ineffective erythropoiesis in patients suffering from sickle cell disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1603244A (en) * 1977-05-20 1981-11-18 Max Planck Gesellschaft Medicaments for the suppression of pathological processes
FR2511366A1 (fr) * 1981-08-11 1983-02-18 Sanofi Sa Nouveaux derives de la pyridazine, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent
US4590194A (en) * 1981-10-05 1986-05-20 Sterling Drug Inc. 3-[methyl or dimethyl)amino]-6-(pyridinyl)pyridazines and their cardiotonic use
IE860511L (en) * 1985-03-01 1986-09-01 Alfa Farmaceutici Spa "Benzoyl urea derivatives having anti-tumor activity"
US5055451A (en) * 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
DE4134467A1 (de) * 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5081145A (en) * 1990-02-01 1992-01-14 Merck Frosst Canada, Inc. Indole-2-alkanoic acids compositions of and anti allergic use thereof
WO1991015577A1 (en) * 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE
DE69226820T2 (de) * 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
ES2114654T3 (es) 1993-06-08 1998-06-01 Vertex Pharma Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta.

Also Published As

Publication number Publication date
DE69408598T2 (de) 1998-09-17
DK0628550T3 (da) 1998-09-28
ATE163412T1 (de) 1998-03-15
HUT67413A (en) 1995-04-28
FI942693L (fi) 1994-12-09
IL109918A0 (en) 1994-10-07
CZ140194A3 (en) 1995-01-18
US6121266A (en) 2000-09-19
US6995261B2 (en) 2006-02-07
SK69794A3 (en) 1995-02-08
NO942133L (no) 1994-12-09
EP0628550A3 (en) 1995-01-18
HU9401714D0 (en) 1994-09-28
JPH0769894A (ja) 1995-03-14
CA2125359A1 (en) 1994-12-09
RU94019984A (ru) 1997-04-10
US20040110725A1 (en) 2004-06-10
NO306061B1 (no) 1999-09-13
FI942693A0 (fi) 1994-06-08
NO942133D0 (no) 1994-06-08
FI942693A7 (fi) 1994-12-09
NZ260698A (en) 1996-09-25
KR950000673A (ko) 1995-01-03
US6624166B1 (en) 2003-09-23
AU6455694A (en) 1994-12-15
AU693786B2 (en) 1998-07-09
DE69408598D1 (de) 1998-04-02
EP0628550B1 (en) 1998-02-25
EP0628550A2 (en) 1994-12-14

Similar Documents

Publication Publication Date Title
ES2114654T3 (es) Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta.
DK0927161T3 (da) Substitueret cyklisk amin-metalloproteaseinhibitorer
ES2133163T3 (es) Esteres (o tioesteres) del acido n-acilsulfamico y esteres (o tioesteres) del acido n-sulfonilcarbamico como agentes hipercolesterolemicos.
ES518503A0 (es) Un metodo de preparar compuestos de fosforos.
IL66596A0 (en) Antihypertensive substituted n-alkanoylheterocyclic carboxylic acid derivatives,compositions containing them and methods for their use
DE69413167D1 (de) Peptid-Phosphinyloxymethyl-Ketonen als Inhibitoren von Interleukin-1 beta-konvertierenden Enzymen
GB2303851A (en) Pharmaceutical diketopiperazine compounds
AR009358A1 (es) Compuesto espirociclico inhibidor de la metaloproteasa
MX9305364A (es) Compuestos inhibidores de proteasa retroviral, metodo para su produccion y composicion farmaceutica que los comprende.
ES2092751T3 (es) Nuevos 2-sacarinilmetil aril carboxilatos utiles como inhibidores de enzimas proteoliticos y composiciones y metodos de empleo de los mismos.
ES2068497T3 (es) Derivados de urea, su produccion, y composiciones farmaceuticas que los contienen.
DK58588A (da) 2-aminoacetamidderivat
AR240835A2 (es) Procedimiento para la preparacion de nuevos derivados de gonadoliberina que contienen un grupo beta-aspartilo
ATE40821T1 (de) Gesaettigte zykloalkyl-c-pyrrole-2(1h)essigs|ureamide und deren derivate.
ATE48414T1 (de) Gesaettigte cycloalkyl(b)pyrrol 1(2h)essigs|ureamide und deren derivate.
YU51398A (sh) Polihidroksifenol derivati i preventivni i terapeutski agensi za oboljenja kosti i hrskavice koji sadrže iste
DE69629703D1 (de) Synthese von optisch reinen verbindungen als garft-inhibitoren und deren zwischenprodukte
ATE244714T1 (de) 1-(3-aminoindazol-5-yl)-3-phenylmethyl cyclische harnstoffe und ihre verwendung als hiv protease inhibitoren
MX9700828A (es) Analogos del acido aspartico como inhibidores de la enzima que convierte a la interleucina-1 beta.
ES8304989A1 (es) Mejoras introducidas en un procedimiento para la preparacion hidroximidatos y tiolhidroximidatos heterobiciclicos y de- rivados ester carbomatos de los mismos.
NO911236D0 (no) Fremgangsmaate for fremstilling av haloethyl-substituerte steroidale enzyminhibitorer.
ES2026452T3 (es) Un procedimiento para preparar 6h-isoxazolo/ 3,4-d/pirazolo/3,4-b/piridinas.
ATE44149T1 (de) N,n-dialkylaminoalkyl-hexahydro-5-oxo-1hpyrrolizin-3-carboxamide.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 628550

Country of ref document: ES